A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow.
Alkyl-lysophospholipid compounds which are selectively cytotoxic to neoplastic cells and relatively sparing of normal marrow progenitor cells are appealing as purging agents to rid remission marrows of residual leukemic cells. A multi-institutional phase II study was conducted in 57 patients with acute leukemia (50 AML and 7 ALL) in which remission marrows were purged in vitro and reinfused after ablative chemotherapy. The median time for granulocyte recovery to 500/microliter was 33 days and for platelet recovery to 25000/microliter was 46 days. The overall DFS and survival was 37% and 46% respectively. Transplantation in first remission gave a better survival than transplant in a subsequent remission.
Vogler
W R
WR
Emory University, Atlanta, Georgia, USA.
Berdel
W E
WE
Geller
R B
RB
Brochstein
J A
JA
Beveridge
R A
RA
Dalton
W S
WS
Miller
K B
KB
Lazarus
H M
HM
D000293:Adolescent; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010742:Phospholipid Ethers / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D010742:Phospholipid Ethers; C026659:edelfosine